Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Grifols And 2 Other Stocks That Might Be Trading Below Estimated Value

In This Article:

As global markets grapple with rising Treasury yields and tepid economic growth, investors are increasingly focused on identifying stocks that may be trading below their intrinsic value. In this environment, a good stock is often characterized by strong fundamentals and the potential for future growth, making it an attractive option for those seeking value amidst market fluctuations.

Top 10 Undervalued Stocks Based On Cash Flows

Name

Current Price

Fair Value (Est)

Discount (Est)

Trimegah Bangun Persada (IDX:NCKL)

IDR890.00

IDR1777.58

49.9%

Provident Financial Services (NYSE:PFS)

US$19.03

US$37.92

49.8%

Western Alliance Bancorporation (NYSE:WAL)

US$84.27

US$168.24

49.9%

California Resources (NYSE:CRC)

US$52.32

US$104.35

49.9%

Geovis TechnologyLtd (SHSE:688568)

CN¥40.77

CN¥81.16

49.8%

Beyout Investment Group Holding Company - K.S.C. (Holding) (KWSE:BEYOUT)

KWD0.395

KWD0.79

49.9%

Acerinox (BME:ACX)

€8.52

€16.98

49.8%

Enento Group Oyj (HLSE:ENENTO)

€18.40

€36.57

49.7%

ChromaDex (NasdaqCM:CDXC)

US$3.58

US$7.15

49.9%

Fine Foods & Pharmaceuticals N.T.M (BIT:FF)

€8.36

€16.70

49.9%

Click here to see the full list of 959 stocks from our Undervalued Stocks Based On Cash Flows screener.

Let's explore several standout options from the results in the screener.

Grifols

Overview: Grifols, S.A. is a plasma therapeutic company operating in Spain, the United States, Canada, and internationally with a market cap of approximately €6.40 billion.

Operations: Grifols generates revenue primarily from its Biopharma segment (€5.78 billion), followed by the Diagnostic segment (€651.33 million) and Bio Supplies segment (€186.91 million).

Estimated Discount To Fair Value: 47.2%

Grifols appears undervalued, trading at €10.32, significantly below its estimated fair value of €19.55. Despite recent volatility, the company has become profitable this year and is expected to see substantial earnings growth of 28.6% annually over the next three years, outpacing the Spanish market's average growth rate. However, interest payments are not well covered by earnings, which could pose financial challenges despite promising revenue forecasts and strategic product developments like VISTASEAL™ in pediatric surgery.

BME:GRF Discounted Cash Flow as at Oct 2024
BME:GRF Discounted Cash Flow as at Oct 2024

IKD

Overview: IKD Co., Ltd. specializes in the research, development, production, and sale of automotive aluminum alloy precision die castings across the United States, Europe, and Asia with a market cap of CN¥15.13 billion.